IT 139

Drug Profile

IT 139

Alternative Names: IT-139; KP 1339; NKP-1339

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Vienna
  • Developer Intezyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 15 Mar 2018 Intezyne plans a phase Ib/IIa trial of IT 139 for Solid tumours (Combination therapy) in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top